Products Pembrolizumab
Pembrolizumab Phase 2 Completed ⚡ Active Oct 11, 2016 → Mar 1, 2023
About Pembrolizumab Pembrolizumab is a phase 2 stage product being developed by Merck for Anal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02919969. Target conditions include Anal Cancer.
Clinical Trials (20) NCT ID Phase Status Start Completion Indication NCT02083484 Pre-clinical Completed — — Melanoma NCT07302347 Phase 1/2 Recruiting Mar 31, 2026 Dec 31, 2029 Malignant Neoplasm NCT07089992 Phase 2 Recruiting Dec 4, 2025 Dec 1, 2028 Sarcoma NCT07007273 Phase 2 Recruiting Jun 20, 2025 Jul 1, 2030 Cutaneous Sarcoma NCT04569461 Phase 2 Withdrawn Jun 1, 2025 Dec 1, 2026 Prostate Cancer NCT05815927 Phase 3 Recruiting May 23, 2025 Mar 30, 2030 Oligometastatic Squamous Cell Carcinoma of the Head and Neck NCT05852223 Phase 2 Recruiting Dec 20, 2024 Dec 1, 2027 Differentiated Thyroid Cancer NCT05879120 Phase 2 Withdrawn Jul 30, 2024 Oct 2, 2024 Recurrent Glioblastoma NCT06004336 Phase 2 Recruiting Oct 31, 2023 Jan 1, 2029 Oligometastatic Renal Cell Carcinoma NCT05496036 Phase 2 Recruiting Feb 13, 2023 Sep 30, 2027 Merkel Cell Carcinoma NCT05131919 Phase 2 Active Dec 22, 2022 Jul 1, 2031 Colorectal Cancer NCT05197322 Phase 2 Recruiting Jul 20, 2022 Dec 1, 2028 Adenocarcinoma of the Colon NCT05406713 Phase 2 Active Jul 13, 2022 Jan 1, 2028 Muscle Invasive Bladder Carcinoma NCT05025813 Phase 2 Recruiting Jun 28, 2022 Jun 1, 2027 Cutaneous Squamous Cell Carcinoma of the Head and Neck NCT06413095 Phase 1 Completed Jun 1, 2022 Jun 22, 2023 Head and Neck Squamous Cell Carcinoma NCT05191472 Phase 2 Terminated May 3, 2022 Dec 31, 2023 Multiple Myeloma NCT05204160 Phase 2 Withdrawn Apr 11, 2022 Feb 27, 2024 Plasma Cell Myeloma NCT04575961 Phase 2 Active Feb 22, 2022 Mar 1, 2028 Ovarian Cancer NCT04417166 Phase 2 Recruiting Feb 11, 2022 Dec 1, 2026 Lymphoma, Extranodal NK-T-Cell NCT05188508 Phase 2 Recruiting Jan 14, 2022 Jan 1, 2027 Glioma
Product Company Stage Hype Score aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib Johnson & Johnson Approved Acetaminophen Johnson & Johnson Phase 2 HRF2105 patch + Loxoprofen patch + placebo Jiangsu Hengrui Medicine Phase 2 Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation Jiangsu Hengrui Medicine Phase 1 Bupivacaine Liposome Injection Jiangsu Hengrui Medicine Approved Paracetamol injection + Normal Saline injection + Morhpine PCA Jiangsu Hengrui Medicine Phase 2/3 Bupivacaine Liposome Injection + Bupivacaine Hydrochloride Injection Jiangsu Hengrui Medicine Phase 2 Vandetanib + Capecitabine + Oxaliplatin + Bevacizumab AstraZeneca Phase 1 Org 28611 + morphine sulfate + Placebo Merck Phase 2 Cetuximab + Mitomycin C + 5-Fluoruracil Merck Phase 1 Pembrolizumab + Paclitaxel + Carboplatin + Pembrolizumab Merck Phase 2 9-valent HPV vaccination Merck Phase 2 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Phase 2 Gardasil Merck Pre-clinical Sample collection Novartis Phase 2 Atezolizumab plus Tiraglolumab Roche Phase 2 MPDL3280A + mDCF Roche Phase 2 panitumumab, mytomicin C, 5-FU, radiation Amgen Phase 2 oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloride Pfizer Phase 1 Ibuprofen 600 mg Immediate Release/Extended Release Caplet Pfizer Phase 3
Other Products from Merck